Oxatomide
SIGMA/O9387 - ≥99%
Synonym: 1-
CAS Number: 60607-34-3
Empirical Formula (Hill Notation): C27H30N4O
Molecular Weight: 426.55
EC Number: 262-320-9
MDL Number: MFCD00211147
Linear Formula: C27H30N4O
Product Type: Chemical
| assay | ≥99% |
| color | white |
| form | powder |
| InChI | 1S/C27H30N4O/c32-27-28-24 |
| InChI key | BAINIUMDFURPJM-UHFFFAOYSA |
| originator | Johnson & Johnson |
| Quality Level | 100 ![]() |
| SMILES string | O=C1Nc2ccccc2N1CCCN3CCN(C |
| solubility | DMSO: soluble |
| ethanol: soluble |
| Biochem/physiol Actions: | Oxatomide is an anti-allergy compound. It suppresses platelet activating factor (PAF)-induced bronchoconstriction and inhibits leukotriene production. |
| Biochem/physiol Actions: | Oxatomide, found in several antihistamines, can suppress mast cell degranulation. It can be used as an alternative to individuals with allergic rhinitis who do not or poorly respond to more established antihistamines. Oxatomide exhibits both antihistamine and anti-inflammatory properties. It exhibits therapeutic effects against asthma and vulvar lichen sclerosus. |
| Features and Benefits: | This compound was developed by Johnson & Johnson . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| General description: | Oxatomide, a histamine H1-receptor antagonist, is bound at high levels to plasma proteins in human blood. |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H302 |
| Hazard Codes | Xn |
| Risk Statements | 22 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥99% |
| UNSPSC | 51111800 |


